A Phase II investigator-led trial investigating AstraZeneca’s Fasenra (benralizumab) treating eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD) has ...

Fasenra is approved for treating severe eosinophilic asthma. AZN is also evaluating Fasenra in late-stage studies for treating nasal polyps and COPD among others. Last month, the FDA approved ...

AZ said Fasenra (benralizumab) has been approved as an add-on maintenance treatment in adults with severe eosinophilic asthma, inadequately controlled on standard inhaled corticosteroid and long ...

The IL-5 inhibitor is already available under the Fasenra brand name for maintenance use in severe eosinophilic asthma, but a new study conducted by researchers at King's College London (KCL ...

Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.

Researchers are tackling neutrophilic asthma, successfully developing one of the first mouse models of the condition.

Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

an Asthma Control Questionnaire score was deemed “best predictor” of 12-month remission in patients with severe eosinophilic asthma, according to study data. “The [5-item Asthma Control ...

Medscape Medical News, November 14, 2024 Fasenra Approved in Europe for Rare Blood Vessel Disorder The drug was originally approved for adults with severe eosinophilic asthma. Medscape Medical ...

Blue Cross Blue Shield (BCBS), under its parent company Health Care Service Corporation, is changing how certain asthma injections are administered.

especially because it already has credibility from asthma indications.” Fasenra’s mechanism of action, targeting IL-5 to reduce eosinophilic inflammation, positions it to address unmet needs ...